GlassScriptPhysician profile
Christopher John Strain
NPI 1407611775
$1,434.05
in general payments reported to CMS, 2019-2025
23 companies · $1,057 in 2025
The $1,057 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $378 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $444.33 | 2024-2025 | |
| Corcept Therapeutics | $145.43 | 2024-2025 | Korlym |
| Lilly USA, LLC | $122.18 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $82.06 | 2025 | |
| Phathom Pharmaceuticals, INC. | $71.76 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $66.92 | 2024-2025 | Rexulti |
| Amgen INC. | $61.35 | 2024-2025 | Krystexxa |
| Boston Scientific Corporation | $55.43 | 2024-2025 | Watchman Flx |
| Pfizer INC. | $40.23 | 2025 | |
| Dexcom, INC. | $36.22 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $35.83 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $32.97 | 2024-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $32.25 | 2024 | Spravato |
| Edwards Lifesciences Corporation | $28.61 | 2025 | |
| Coopersurgical, INC. | $27.51 | 2025 | Paragard T 380a |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $25.93 | 2025 | Recorlev |
| Neurocrine Biosciences, INC. | $22.01 | 2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $21.03 | 2024 | Trintellix |
| Inspire Medical Systems, INC. | $20.03 | 2025 | Inspire |
| 3b Medical, INC. | $17.74 | 2025 | Luna |
| Corium, LLC | $16.39 | 2024 | Azstarys |
| Axsome Therapeutics, INC. | $14.08 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $13.76 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Strain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.